Reducing travel-related SARS-CoV-2 transmission with layered mitigation measures: symptom monitoring, quarantine, and testing.
COVID-19
Quarantine
SARS-CoV-2
Testing
Travel
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
14 04 2021
14 04 2021
Historique:
received:
19
01
2021
accepted:
25
03
2021
entrez:
14
4
2021
pubmed:
15
4
2021
medline:
18
5
2021
Statut:
epublish
Résumé
Balancing the control of SARS-CoV-2 transmission with the resumption of travel is a global priority. Current recommendations include mitigation measures before, during, and after travel. Pre- and post-travel strategies including symptom monitoring, antigen or nucleic acid amplification testing, and quarantine can be combined in multiple ways considering different trade-offs in feasibility, adherence, effectiveness, cost, and adverse consequences. We used a mathematical model to analyze the expected effectiveness of symptom monitoring, testing, and quarantine under different estimates of the infectious period, test-positivity relative to time of infection, and test sensitivity to reduce the risk of transmission from infected travelers during and after travel. If infection occurs 0-7 days prior to travel, immediate isolation following symptom onset prior to or during travel reduces risk of transmission while traveling by 30-35%. Pre-departure testing can further reduce risk, with testing closer to the time of travel being optimal even if test sensitivity is lower than an earlier test. For example, testing on the day of departure can reduce risk while traveling by 44-72%. For transmission risk after travel with infection time up to 7 days prior to arrival at the destination, isolation based on symptom monitoring reduced introduction risk at the destination by 42-56%. A 14-day quarantine after arrival, without symptom monitoring or testing, can reduce post-travel risk by 96-100% on its own. However, a shorter quarantine of 7 days combined with symptom monitoring and a test on day 5-6 after arrival is also effective (97--100%) at reducing introduction risk and is less burdensome, which may improve adherence. Quarantine is an effective measure to reduce SARS-CoV-2 transmission risk from travelers and can be enhanced by the addition of symptom monitoring and testing. Optimal test timing depends on the effectiveness of quarantine: with low adherence or no quarantine, optimal test timing is close to the time of arrival; with effective quarantine, testing a few days later optimizes sensitivity to detect those infected immediately before or while traveling. These measures can complement recommendations such as social distancing, using masks, and hand hygiene, to further reduce risk during and after travel.
Sections du résumé
BACKGROUND
Balancing the control of SARS-CoV-2 transmission with the resumption of travel is a global priority. Current recommendations include mitigation measures before, during, and after travel. Pre- and post-travel strategies including symptom monitoring, antigen or nucleic acid amplification testing, and quarantine can be combined in multiple ways considering different trade-offs in feasibility, adherence, effectiveness, cost, and adverse consequences.
METHODS
We used a mathematical model to analyze the expected effectiveness of symptom monitoring, testing, and quarantine under different estimates of the infectious period, test-positivity relative to time of infection, and test sensitivity to reduce the risk of transmission from infected travelers during and after travel.
RESULTS
If infection occurs 0-7 days prior to travel, immediate isolation following symptom onset prior to or during travel reduces risk of transmission while traveling by 30-35%. Pre-departure testing can further reduce risk, with testing closer to the time of travel being optimal even if test sensitivity is lower than an earlier test. For example, testing on the day of departure can reduce risk while traveling by 44-72%. For transmission risk after travel with infection time up to 7 days prior to arrival at the destination, isolation based on symptom monitoring reduced introduction risk at the destination by 42-56%. A 14-day quarantine after arrival, without symptom monitoring or testing, can reduce post-travel risk by 96-100% on its own. However, a shorter quarantine of 7 days combined with symptom monitoring and a test on day 5-6 after arrival is also effective (97--100%) at reducing introduction risk and is less burdensome, which may improve adherence.
CONCLUSIONS
Quarantine is an effective measure to reduce SARS-CoV-2 transmission risk from travelers and can be enhanced by the addition of symptom monitoring and testing. Optimal test timing depends on the effectiveness of quarantine: with low adherence or no quarantine, optimal test timing is close to the time of arrival; with effective quarantine, testing a few days later optimizes sensitivity to detect those infected immediately before or while traveling. These measures can complement recommendations such as social distancing, using masks, and hand hygiene, to further reduce risk during and after travel.
Identifiants
pubmed: 33849546
doi: 10.1186/s12916-021-01975-w
pii: 10.1186/s12916-021-01975-w
pmc: PMC8043777
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
94Références
BMJ Open. 2020 Aug 5;10(8):e039856
pubmed: 32759252
J Air Transp Manag. 2020 Oct;89:101897
pubmed: 32837029
MMWR Morb Mortal Wkly Rep. 2021 Jan 01;69(5152):1642-1647
pubmed: 33382679
Int J Infect Dis. 2020 Apr;93:284-286
pubmed: 32145466
Math Biosci Eng. 2020 Jun 15;17(4):4165-4183
pubmed: 32987574
J Air Transp Manag. 2020 Oct;89:101920
pubmed: 32874021
JAMA Netw Open. 2020 Jul 1;3(7):e2016818
pubmed: 32735339
Elife. 2020 Feb 24;9:
pubmed: 32091395
Cochrane Database Syst Rev. 2020 Oct 5;10:CD013717
pubmed: 33502002
J Air Transp Manag. 2020 Oct;89:101932
pubmed: 32952318
Sci Adv. 2021 Jan 1;7(1):
pubmed: 33219112
MMWR Morb Mortal Wkly Rep. 2020 Oct 23;69(42):1542-1546
pubmed: 33090983
Comput Methods Biomech Biomed Engin. 2020 Aug;23(11):710-717
pubmed: 32367739
BMJ Open. 2020 Aug 16;10(8):e039652
pubmed: 32801208
BMJ Mil Health. 2021 Jun;167(3):217-218
pubmed: 33122402
MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):100-105
pubmed: 33476316
Emerg Infect Dis. 2020 Jul;26(7):
pubmed: 32364890
JAMA Netw Open. 2021 Jan 4;4(1):e2035057
pubmed: 33410879
Nat Commun. 2021 Jan 7;12(1):356
pubmed: 33414470
PLoS Med. 2020 Sep 22;17(9):e1003346
pubmed: 32960881
J Infect Dis. 2021 Apr 8;223(7):1139-1144
pubmed: 33394052
Clin Infect Dis. 2020 Dec 17;71(10):2663-2666
pubmed: 32442256
Elife. 2021 Feb 23;10:
pubmed: 33620317
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
MMWR Morb Mortal Wkly Rep. 2020 Nov 13;69(45):1681-1685
pubmed: 33180758
JAMA. 2020 Nov 3;324(17):1798
pubmed: 33022035
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Public Health. 2020 May;182:163-169
pubmed: 32334182
N Engl J Med. 2020 Sep 24;383(13):e83
pubmed: 32757517
Emerg Infect Dis. 2020 May;26(5):1052-1054
pubmed: 32091386
J Infect. 2021 May;82(5):186-230
pubmed: 33421447
Trop Med Health. 2020 Sep 14;48:79
pubmed: 32939152
J Occup Environ Med. 2020 Sep;62(9):771-779
pubmed: 32890217
Elife. 2021 Feb 05;10:
pubmed: 33543709
J Infect. 2020 Sep;81(3):357-371
pubmed: 32615199
Ann Intern Med. 2020 Aug 18;173(4):262-267
pubmed: 32422057
Elife. 2020 Jun 22;9:
pubmed: 32568070
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):411-415
pubmed: 32271722
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Epidemics. 2021 Jun;35:100453
pubmed: 33971429
J Travel Med. 2020 Aug 20;27(5):
pubmed: 32597473
Lancet Infect Dis. 2020 Sep;20(9):1025-1033
pubmed: 32445710
J Travel Med. 2020 Dec 23;27(8):
pubmed: 32841354
Euro Surveill. 2020 Feb;25(5):
pubmed: 32046816
J Emerg Med. 2020 Dec;59(6):952-956
pubmed: 33139117
J Air Transp Manag. 2020 Oct;89:101928
pubmed: 32952320
Lancet Infect Dis. 2020 Sep;20(9):993
pubmed: 32860768
J Glob Health. 2020 Dec;10(2):020318
pubmed: 33110520
Lancet. 2020 Apr 25;395(10233):1331-1332
pubmed: 32334692
Int J Infect Dis. 2020 Sep;98:51-58
pubmed: 32579906
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404
Science. 2020 Apr 24;368(6489):395-400
pubmed: 32144116